Ontario source: bounded use
Ovarian cancer pathway map supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Ontario.
sources for this section:Ontario ovarian pathway
Source-attributed clinical priorities
- Assess persistent bloating, early satiety, pelvic or abdominal pain, urinary change, mass and family cancer history.
- Use pelvic imaging and biomarkers within the provincial pathway, recognizing that a marker alone cannot diagnose or exclude cancer.
- Refer a suspicious adnexal mass to gynecologic oncology before definitive surgery when feasible.
- A normal tumor marker does not exclude ovarian cancer in a patient with a concerning mass or persistent symptoms.
sources for this section:Ontario ovarian pathway
Practical assessment and management workflow
1
Record symptom frequency and persistence, menopausal status, family history and prior breast or ovarian cancer.
2
Examine abdomen and pelvis with consent and arrange pelvic ultrasound and indicated biomarkers.
3
Use a Canadian risk assessment and refer a suspicious adnexal mass to gynecologic oncology.
4
Coordinate genetic assessment and ensure diagnostic results and operative planning reach the specialist team.
sources for this section:Ontario ovarian pathway
Safety, red flags and urgent escalation
- Acute pain with a mass may represent torsion or rupture and needs emergency assessment.
- Ascites, bowel obstruction or major respiratory compromise requires urgent care.
- Avoid definitive surgery outside a gynecologic-oncology plan when malignancy is strongly suspected and transfer is feasible.
sources for this section:Ontario ovarian pathway
Confirm the local pathway before acting
Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:Ontario ovarian pathway
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Ontario ovarian pathway
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Ontario Health (Cancer Care Ontario)Ovarian cancer pathway mapaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.